SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Log In Sign Up Schedule Free 15‑min Call

Top Pharma Companies in India by Market Cap

BSE Sensex 77641.05
875.13 (1.14%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
121	Glaxosmithkline Pharmaceuticals Ltd.	Q V+ PT	44,744 Mid Cap	2,614 (-1.03%)	43.19	19.6	5.49	17.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
122	Procter & Gamble Health Ltd.	Q V+ PT	11,088 Small Cap	6,638.60 (-0.62%)	33.92	21.14	4.31	11.97	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
123	Torrent Pharmaceuticals Ltd.	Q V+ PT	1,86,354 Large Cap	4,882 (-0.35%)	86.14	22.16	11.80	13.74	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
124	Astrazeneca Pharma India Ltd.	Q V PT	20,174 Small Cap	8,189.70 (1.49%)	107.58	23.29	22.84	15.69	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
125	Sanofi Consumer Healthcare India Ltd.	Q V+ PT	10,860 Small Cap	4,734.85 (0.41%)	42.11	24.04	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Artemis MedicareServ	300.90	8.55%
Suven Life Sciences	309.10	5.05%
Divis Laboratories	7,781.20	4.86%
SMS Pharmaceuticals	397.50	4.36%
Dr. Lal Pathlabs	1,881.75	4.18%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Hester Biosciences	2,460.10	-2.57%
Fischer Medical	35.99	-2.31%
3B Blackbio Dx	1,275	-1.63%
Fermenta Biotech	450	-1.37%
Indraprastha Medical	363.50	-1.29%

News about Top Pharma Companies in India

29

Jul, 2026

AstraZeneca Pharma India informs about certificate

AstraZeneca Pharma India has informed that it enclosed the Certificate dated July 27, 2026 issued by Integrated Registry Management Services, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026.

The above information is a part of company’s filings submitted to BSE.

21

Jul, 2026

GlaxoSmithKline Pharmaceuticals informs about board meeting

Pursuant to Regulations 29 & 33 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR), GlaxoSmithKline Pharmaceuticals has informed that a meeting of the Board of Directors of our Company will be held on Monday, 3rd August 2026, to consider, approve and take on record the Un-audited financial results for the first quarter ended 30th June 2026.

The above information is a part of company’s filings submitted to BSE.

21

Jul, 2026

AstraZeneca Pharma India informs about resignation of CFO

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III thereto, AstraZeneca Pharma India has informed that, Bhavana Agrawal, Executive Director and Chief Financial Officer (‘CFO’) has communicated her resignation from the position of CFO (Key Managerial Personnel) of the Company with effect from the close of business hours on August 31, 2026, pursuant to her appointment to a regional role within the AstraZeneca Group. A copy of the resignation letter is enclosed as Annexure – A. Further, the details as required under the SEBI Master Circular SEBI/HO/49/14/14(7)2025- CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed as Annexure – B.

The above information is a part of company’s filings submitted to BSE.

18

Jul, 2026

Torrent Pharmaceuticals informs about updates

Torrent Pharmaceuticals has informed that the Curatio Inc., Philippines Wholly Owned Subsidiary (WOS) of the Company domiciled in Philippines, has been voluntarily dissolved with effect from July 10, 2026. The Company has received communication of above dissolution on July 17, 2026 from Philippines. The details as required under Regulation 30 of Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed as Annexure.

The above information is a part of company’s filings submitted to BSE.

18

Jul, 2026

Torrent Pharmaceuticals informs about ESG rating

Pursuant to the provisions of Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026, Torrent Pharmaceuticals has informed that Crisil ESG Ratings & Analytics Limited, a SEBI registered ESG Rating Provider (Crisil ESG Ratings), has independently assigned the rating of ‘Crisil ESG 66’ and the Core ESG rating of ‘Crisil Core ESG 74’.

The above information is a part of company’s filings submitted to BSE.

16

Jul, 2026

Torrent Pharmaceuticals informs about board meeting

Torrent Pharmaceuticals has informed that a meeting of the Board of Directors will be held on Thursday, 30-Jul-26, to consider and approve the Unaudited Standalone and Consolidated Financial Results (with limited review) for the quarter ended on 30-Jun-26.

The above information is a part of company’s filings submitted to BSE.

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	KMC Speciality Hospitals (India) Ltd.	2,124 Crore
2	Nectar Lifesciences Ltd.	199 Crore
3	Dishman Carbogen Amcis Ltd.	2,857 Crore
4	Shalby Ltd.	1,742 Crore
5	Unichem Laboratories Ltd.	3,763 Crore
6	Lincoln Pharmaceuticals Ltd.	1,161 Crore
7	Fabtech Technologies Ltd.	664 Crore
8	Krsnaa Diagnostics Ltd.	1,731 Crore
9	Natco Pharma Ltd.	16,561 Crore
10	Indoco Remedies Ltd.	2,105 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,769	59,301	38.21	12.49	26.17	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,882	1,86,354	86.14	22.16	44.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,459	1,09,494	20.53	4.89	11.88	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,382	41,675	39.47	9.21	26.67	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,668	67,559	30.92	4.83	22.42	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,782	94,987	97.82
Sai Life Sciences Ltd. (S)	Very Good	1,309	27,605	57.56
Aurobindo Pharma Ltd. (M)	Very Good	1,591	89,212	37.52
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,882	1,86,354	35.15
Lupin Ltd. (M)	Somewhat Good	2,459	1,09,494	22.15
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,309	27,605	80.84	11.01	42.51	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,382	41,675	39.47	9.21	26.67	13.54
Mankind Pharma Ltd. (M)	Very Good	2,605	1,08,129	53.07	6.61	33.20	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,124	1,09,686	21.76	4.22	13.36	13.52
Lupin Ltd. (M)	Somewhat Good	2,459	1,09,494	20.53	4.89	11.88	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,459	1,09,494	20.53	4.89	11.88	32.37
Abbott India Ltd. (M)	Very Good	27,769	59,301	38.21	12.49	26.17	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,144	94,790	29.42	2.48	15.11	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,124	1,09,686	21.76	4.22	13.36	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,982	4,74,397	41.33	5.68	23.70	14.41

You have 6 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks